ALC offers free laser treatment samples
This article was originally published in The Rose Sheet
Executive Summary
"Largest provider of aesthetic services in the U.S.," with more than 220 locations nationwide, American Laser Centers announces promotion offering consumers one free trial treatment of their choice this summer. Consumers can try ALC's laser hair removal combining pulsed, high-intensity light with radiofrequency therapy, which is backed by "the industry's only written two-year guarantee for laser hair removal," the company says; body contouring and cellulite reduction, skin rejuvenation and skin tightening are also options. Treatment packages are available at nearly 40% reduced rates, firm adds. Dermatologists generally agree that while emerging home-use aesthetic devices do not compare in their performance with the professional technologies on which they are based, they represent an increasingly attractive option for consumers due to their convenience and affordability (1"The Rose Sheet" March 9, 2009). Palomar Medical Technologies and Johnson & Johnson received first FDA approval for home laser treatment of periorbital wrinkles in June (2"The Rose Sheet" June 8, 2009). Cynosure and Unilever will concentrate initially on development of a light-based device for skin rejuvenation under a deal announced July 1 (3"The Rose Sheet" July 6, 2009)
You may also be interested in...
Dermatologists Optimistic About Future Of Home-Use Aesthetic Devices
Dermatologists agree that home-use aesthetic devices still pale in comparison with the professional treatments on which they are based; however, the technology is developing rapidly and likely will soon be a cost-effective option for consumers, they say
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.